Testing the Addition of Chemotherapy Drug, Cisplatin, to Usual Radiation Therapy for Patients with Head and Neck Cancer
The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.
Participants will be assigned to receive either radiation therapy, or radiation therapy along with cisplatin. Both groups will receive treatment for 6 weeks with the doctor following their condition for 10 years after treatment.
- IRB Number: 1908611001
- Research Study Identifier: NCT02734537
- Principal Investigator: Greg Durm, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required